Discontinuation of Risperidone in Dementia Patients
Critical Safety Considerations and Evidence
- A 2018 randomized controlled trial found that risperidone was associated with higher delirium symptom severity scores compared to placebo and resulted in poorer overall survival in long-term follow-up, in a population of patients in palliative care settings, indicating a high level of evidence against its use in this context 1
- The European Society for Medical Oncology (ESMO) guidelines state that administration of either haloperidol or risperidone has no demonstrable benefit in symptomatic management of mild-to-moderate delirium and is not recommended, providing a strong guideline recommendation against its use 2
Cognitive Side Effects and Management
- Extrapyramidal symptoms, which can manifest as thought blocking and cognitive slowing, occur in a dose-dependent manner with risperidone, even at low doses in elderly patients, according to the American Academy of Family Physicians, highlighting the need for caution when prescribing this medication to older adults 3
Alternative Management Strategies
- Non-pharmacological interventions should be first-line, including environmental modifications, reorientation strategies, and caregiver education, as recommended by the ESMO guidelines, providing a low-risk alternative to pharmacological treatment 2
- If pharmacological treatment is absolutely necessary for severe agitation threatening harm, consider quetiapine 12.5-25 mg daily or olanzapine 2.5 mg daily, but use at the lowest effective dose for the shortest duration possible, as advised by the American Academy of Family Physicians and ESMO guidelines 2, 3
Common Pitfalls to Avoid
- Do not increase the risperidone dose in response to worsening symptoms, as this will likely worsen cognitive function further, according to Praxis Medical Insights, emphasizing the importance of avoiding dose escalation 4
- Do not assume behavioral symptoms require antipsychotics; in dementia patients, these medications often cause more harm than benefit, as highlighted by the Annals of Oncology and ESMO guidelines, providing strong evidence against the routine use of antipsychotics in this population 1, 2